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Abstract: Transforming growth factor beta (TGFB) is a pleiotropic cytokine known to be 
dysregulated in many neurodegenerative disorders and particularly in amyotrophic lateral sclerosis 
(ALS). This motor neuronal disease is non-cell autonomous, as it affects not only motor neurons but 
also the surrounding glial cells, and the target skeletal muscle fibers. Here, we analyze the multiple 
roles of TGFB in these cell types, and how TGFB signaling is altered in ALS tissues. Data reported 
support a crucial involvement of TGFB in the etiology and progression of ALS, leading us to 
hypothesize that an imbalance of TGFB signaling, diminished at the pre-symptomatic stage and 
then increased with time, could be linked to ALS progression. A reduced stimulation of the TGFB 
pathway at the beginning of disease blocks its neuroprotective effects and promotes glutamate 
excitotoxicity. At later disease stages, the persistent activation of the TGFB pathway promotes an 
excessive microglial activation and strengthens muscular dysfunction. The therapeutic potential of 
TGFB is discussed, in order to foster new approaches to treat ALS. 
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1. Introduction 
Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disorder affecting the motor system. 
Nevertheless, it implicates different cell types: motor neurons are the main affected cells, but glial 
and skeletal muscle cells are strongly implicated and able to deeply modulate the disease onset and 
course. The neuromuscular system is a complex network; one of the most important factors 
influencing its development and maintenance is the transforming growth factor beta (TGFB), a 
pleiotropic molecule also known to be dysregulated in ALS patients. The aim of this review is to 
summarize the current knowledge of the different roles of TGFB in ALS. We will briefly describe why 
ALS is also considered a non-cell-autonomous disease, and the general features of the TGFB family; 
then, we will analyze the roles of TGFB on the multiple cell types involved in ALS, and we will 
discuss the TGFB pathway as a potential pharmacological target. We will only briefly mention the 
multiple effects of TGFB on the immune system in ALS, as it is a field that deserves a separate 
discussion, due to the various and multifaceted roles exerted by TGFB on this system. 
2. Amyotrophic Lateral Sclerosis as a Non-Cell-Autonomous Disease 
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ALS is a disease affecting upper and lower motor neurons, with an incidence of 1–2/100,000 per 
year, and mean survival of 3–5 years after diagnosis [1]. ALS can occur in two different forms, 
sporadic (sALS, 90–95% of cases) and familial (fALS, 5–10% of cases), and it can also appear as a pure 
motor phenotype or in association with fronto-temporal dementia (ALS-FTD). ALS is characterized 
by a progressive loss of motor neurons, but the precise pathological mechanisms involved are not 
clear as their complex interplay with neighboring and target cells. Mutations in many different genes 
have been associated with fALS, starting from the superoxide dismutase 1 (SOD1) gene (coding for 
an antioxidant enzyme), to the more recently described mutations in TAR DNA-binding protein 43 
(TDP-43), ALS-linked fused in sarcoma/translocated in liposarcoma (FUS/TLS), and other genes (see, 
for review [2]). Recently, 50% of fALS cases have been associated with an alteration of the 
chromosome 9 open reading frame 72 (C9orf72), resulting in the expansion of the hexanucleotide 
(G4C2) repeat located in its 5’-untranslated region [3–5]. 
ALS is primarily caused by the death of upper and lower motor neurons. Nevertheless, in the 
last 15 years, besides the main classical “neuron-centric” view of ALS, a number of research studies 
evidenced that ALS could also be a non-cell-autonomous disease [6,7]. Data have been mostly 
obtained using ALS mouse models, but they may also be linked to sALS cases [8]. Glial and skeletal 
muscle cells demonstrated their ability to trigger, or modulate, ALS. The analysis of chimeric mice 
indicated that the restricted expression of human mutant SOD1 (mutSOD1) in motor neuron is not 
sufficient to induce a cell-autonomous degeneration of motor neurons [9]. Moreover, utilizing floxed 
mutSOD1 gene, it has been demonstrated that the damaging process starts in motor neurons and 
determines the disease onset, with little influence on its progression [6]. Conversely, mutSOD1 
activates glial cells exacerbating the disease progression, while motor neuronal mutSOD1 has little 
influence on the progression of ALS [6]. 
Among the non-neuronal neighbors of ALS motor neurons, glial cells are the most investigated, 
so far. Astrocytes, microglia, oligodendrocytes, and Schwann cells are all able to modulate ALS 
pathology, and gliosis is a hallmark of ALS from an immuno-histological point of view (see, for 
review [10,11]).  
Activated and proliferating astrocytes become neurotoxic, and no longer provide the metabolic 
support to motor neurons, but secrete cytokines or other toxic factors (among which is the TGFB) that 
are critical for determining the rate of disease progression [12,13]. Furthermore, activated astrocytes 
reduce the expression of the excitatory amino acid transporter-2, that is mandatory for glutamate re-
uptake from the synaptic cleft into astrocyte, leading to excitotoxicity in motor neurons [14].  
Microglia have long been known to be activated in ALS affected tissues, probably through the 
innate immune system. The extent of its activation correlates with the severity of the upper motor 
neuron involvement [15]. The non-cell-autonomous mechanisms of toxicity of microglia include the 
secretion of pro-inflammatory cytokines [16]. The reduction of mutSOD1 toxicity within microglia 
slows the progression of the disease, suggesting that microglia might contribute to the 
neurodegenerative processes of ALS [17]. Other studies indicated that a decreased number of 
microglial cells is present at the pre-symptomatic stage in mouse models, while two distinct microglia 
populations can be identified after symptom manifestation [18]. Whether microglial cells are 
beneficial or detrimental to motor neurons is already an open question. Probably, they exert a 
surveillance role on motor neurons and restore the correct environment after an injury but, when 
constitutively activated in the presence of a chronic stress (such as that causing ALS), they may 
become toxic. 
Other glial cell types are important for motor neuron functionality. Oligodendrocytes provide 
metabolic support to central nervous system (CNS) neurons and support their survival, while 
Schwann cells are strictly related to motor neuron axons and support axonal development and 
regeneration in the peripheral nervous system (PNS). Recent studies implicate oligodendrocytes in 
ALS pathogenesis, through both myelin sheath disruption and the reduction of the monocarboxylate 
transporter 1 [19]. Furthermore, it has been shown that oligodendrocytes isolated from human ALS 
patients are able to induce motor neuron death in a co-culture system [20]. Regarding Schwann cells, 
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few studies addressed their role in ALS, suggesting that axonal degeneration may occur earlier than 
myelin degeneration.  
In addition to neighboring cells, motor neurons can also be influenced by their target, the skeletal 
muscle cells. It has been shown, at least in fALS, a direct muscular toxicity and/or a functional 
impairment that has denervation and motor neuron death as a consequence [21–23]. Muscle 
dysfunction and neuromuscular junction (NMJ) degeneration occur long before disease onset [24]. A 
contribution to the initiation and progression of muscle atrophy is given by altered ALS satellite cell 
properties [25,26]. Furthermore, muscle gene expression is changed since the early stages of the 
disease [27–29]. Regarding the presence of muscle dysfunction in relation to the expression of other 
mutant genes linked to ALS, it must be recalled that TDP-43 immuno-reactivity is detectable only in 
muscle fiber nuclei without any sarcoplasmic TDP-43 aggregation [30,31]; very recently, it has been 
demonstrated that skeletal muscle contributes to the ALS phenotype also in C9orf72 related cases [32]. 
These authors demonstrated that the presence and the amount of dipeptide repeats in patient’s 
muscles are significantly related to a more severe muscular atrophy. In addition, our previous works 
have indicated that the protein quality control system is a dysfunctional cellular process in ALS 
muscle cells, but these cells seem to be more protected than motor neurons against the presence of 
accumulating misfolded proteins [33–35]. Proteasome activity is impaired by mutSOD1 only in motor 
neurons and not in muscle cells [35]. Nevertheless, we proved that motor neurons are characterized 
by a higher autophagic potential with respect to muscle cells. These results could help to clarify why 
muscle cells seem more protected than motor neurons from misfolded SOD1. Parallel results have 
indicated that muscle cells mainly depend on the proteasome system to quickly remove misfolded 
TDP-43 [33]. As a whole, data indicate that autophagy modulation could be a potential therapeutic 
approach to counteract muscle atrophy in ALS and to promote aggregate removal in motor neurons. 
3. Transforming Growth Factor Beta 
TGFB is a family of cytokines with widespread and diverse effects. During development and in 
adulthood, TGFB family member signals can reach practically all the cells modulating their activities 
[36]. The TGFB superfamily comprises 32 members grouped into different families, including TGFB, 
activin, growth and differentiation factor (GDF), and bone morphogenetic protein (BMP) families 
(Table 1) [37]. Among all these ligands, TGFB1 and myostatin are considered the most implicated in 
skeletal muscle development and function, with shared or contraposed features. 
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Table 1.  Transforming growth factor beta (TGFB) family members, their receptors, and SMAD signaling proteins. 
TGFB Super 
Family 
Family Family Members Type I Receptor Type II Receptor R-SMAD I-SMAD 
TGFB TGFB 1–5 TGFBR1 TGFBR2 SMAD2/3 SMAD7 
ACTIVINS/INHIBIN 
ACTIVIN A, B ACVR1B, ACVR1C ACVR2, ACVR2B SMAD2/3 SMAD7 
INHIBIN A, B / ACVR2 / / 
LEFTTY A, B / / / / 
NODAL / ACVR2, ACVR2B SMAD2/3 SMAD6/7 
BMP 











BMP 9, 10 ALK1 ACVR2, BMPR2 SMAD1/5 SMAD6/7 
BMP 15 BMPR1B BMPR2 SMAD1/5 SMAD6/7 
AMH ACVR1A, BMPR1A AMHR2 SMAD1/5 SMAD6/7 
GDF 
GDF 1, 3 ACVR1B, ACVR1C ACVR2, ACVR2B SMAD2/3 SMAD7 
GDF 8 
(MYOSTATIN) 
ACVR1B, TGFBR1 ACVR2 SMAD2/3 SMAD7 
GDF 9 ACVR1B BMPR2 SMAD2/3 SMAD7 
GDF 11 ACVR1B ACVR2, ACVR2B SMAD2/3 SMAD7 




GDF 15 GFRAL / / / 
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The bioactive TGFB ligands are disulfide-linked dimers cleaved from the C-terminal portion of 
a precursor. Usually, the ligands are homodimeric, but also heterodimers exist. All the ligands of the 
TGFB family bind to two pairs of receptors that are transmembrane serine/threonine protein kinases. 
The binding of the cytokine to the type II receptor (TGFBRII) leads to its activation, and to the 
phosphorylation of the type I receptor (TGFBRI), allowing it to phosphorylate small mother against 
decapentaplegic (SMAD) transcription factors which shuttle between the cytosol and the nucleus 
[36]. In the nucleus, SMADs bind to specific responsive elements (SMAD binding elements, SBEs) 
throughout the genome, activating or repressing a variety of different responsive genes (Figure 1).  
 
Figure 1. Signal Transduction pathways of TGFBs. TGFB dimerization triggers the assembly of a 
heterodimeric complex between Type I and Type II receptors (TGFBRI and TGFBRII). This permits 
TGFBRII to trans-phosphorylate TGFBRI that, in turn, activates the receptor-regulated SMADs 
(SMAD2/3) by phosphorylation. Activated R-SMAD forms a complex with the common SMAD 
(SMAD4) and together translocate into the nucleus through nucleoporins; the complex interacts with 
specific SMAD binding elements (SBEs), regulating gene transcriptional responses. 
There are eight SMAD proteins in mammals: five are receptor regulated (R-SMAD, SMAD1, 2, 
3, 5, 8), two are inhibitory (SMAD6 and 7), and one (SMAD4) is a protein common to all the pathways 
of TGFB family members. In the pathway activated by TGFB ligands, the TGFBRI phosphorylates 
SMAD2 and SMAD3. Receptor-mediated phosphorylation facilitates oligomerization between R-
SMADs and SMAD4. The formation of this complex is mandatory to bring the signal from the cytosol 
to the nucleus, but, so far, SMAD4 specific function is unknown since certain TGFB functions do not 
require SMAD4. SMADs nuclear translocation does not depend on nuclear transport factors or 
importins; they can directly interact with nucleoporins [38]. The SMAD dependent signaling pathway 
of TGFB works ubiquitously in all cell types; however, in a context dependent manner, TGFB can 
activate SMAD-independent signaling cascades, such as PI3K, MAPK, or small GTPases [39]. 
Inhibitory SMADs bind an already activated TGFBRI, leading to the inhibition of the R-SMAD 
phosphorylation and their subsequent translocation into the nucleus and adding a further level of 
regulation of the TGFB/SMAD signaling cascade. 
Once in the nucleus, SMAD complexes target specific promoters to regulate gene expression and 
microRNA processing. R-SMADs can directly bind DNA through SBEs giving gene specificity to the 
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complex, while SMAD4 promotes or inhibits transcriptional activity, recruiting different, tissue-
specific co-regulators [40]. Phosphorylated SMAD (pSMAD) signaling is terminated through 
phosphatase (PPM1A/PP2Cα)-mediated dephosphorylation and SMAD export from the nucleus to 
the cytosol. Alternatively, nuclear pSMADs are targeted for ubiquitination and subsequent cytosolic 
proteasomal degradation [41].  
TGFB signaling can also be “non-canonical”; in this case, its effects are transduced by Smad-
independent pathways, which include ERK MAPKs, a TGFB-activated kinase 1 (TAK1 activating 
JNK, p38K, and NF-κB), and PI3K-AKT [42]. The differential activation of non-SMAD pathways is 
context dependent; for example, in myotubes, the atrophic effect of TGFB seems to be linked to 
ERK1/2 and JNK1/2, in addition to SMADs [43]. 
TGFB regulates a plethora of cellular functions, in different contexts, ranging from embryonic 
development to tumor progression, from immune regulation to tissue fibrosis, and neurotrophic 
response modulation. Dysregulation of the TGFB pathway has been reported also as a common 
feature in neurodegenerative disorders, and among them, in pathologies affecting motor neurons, 
and particularly in ALS. The following paragraphs will summarize alterations in the TGFB pathway 
reported in many different ALS models, both in vivo and in vitro, in addition to those detected in 
patients.  
4. TGFB Plasma Levels in ALS Patients 
Similarly to Parkinson’s and Alzheimer’s patients [44,45], in which an increased concentration 
of TGFB1 was found in the cerebrospinal fluid (CSF) or serum respectively, TGFB1 plasma 
concentration in ALS patients is significantly higher than in the healthy controls, and it positively 
correlates with the disease [46]. Indeed, TGFB1 is increased in the serum of ALS patients at an 
advanced stage of disease; likewise, TGFB1 is also augmented in the CSF of ALS patients with long 
disease duration [47]. A recent study has confirmed the existence of a negative correlation between 
TGFB1 and TGFB3 levels and ALS severity; this study postulated that high levels of TGFB in the 
serum might represent a compensatory mechanism to counteract the pronounced systemic immune 
response typical of the late stage of the disease, by inducing T cells to differentiate into non regulatory 
phenotypes [48]. Even if the increase in plasma TGFB1 levels has been confirmed also in mutSOD1 
transgenic mice [49], whether TGFB1 plasma levels are biomarkers of ALS or not is still an open 
question; in fact, other studies fail to detect the changes of TGFB1 levels in patient CSF compared to 
healthy controls [50], or between fast and slow progressing ALS patients analyzed both at early and 
late stage of disease [49]. 
In the attempt to find specific ALS-susceptibility genes, a single-nucleotide polymorphism in the 
ZNF512B gene has been identified; the ZNF512B gene codes for a transcription factor with a reduced 
ability to promote TGFB signaling [51]. A retrospective analysis of this gene in ALS patients indicated 
a significantly lower probability of survival in patients, carrying the risk allele independently from 
other factors know to be involved in ALS [52]. For this reason, ZNF512B might be a new prognostic 
factor in ALS. 
5. TGFB and ALS-Nervous System 
In the adult rodent nervous system, TGFB1 immunoreactivity is constitutively present only in 
meninges and the choroid plexus in the brain [53,54]. However, TGFB1 mRNA is more widely 
expressed, with intense labeling in cortical layers 2, 3, and 5, hippocampus, retinal ganglionic cells, 
some hypothalamic areas, and the ventral horn of the spinal cord [54,55]. TGFB2 and 3 are 
widespread and distributed [53,54]. The immunoreactivity of TGFB is also present in astroglial cells. 
The expression of TGFBRI and TGFBRII has been demonstrated in neurons, astrocytes, 
oligodendrocytes, microglia, and brain endothelial cells [56,57]. 
TGFBs have multiple functions in the CNS. They enhance synapse formation and synaptic 
transmission [58,59], regulate synaptic plasticity and memory [57], increase the number and length 
of neurites [56], control neuronal migration [60], and cerebral cortex angiogenesis [61]. CNS-TGFB1-
deficient mice have a reduced brain weight and a loss of neurons in the CA1 hippocampal region. 
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These mice show a reduction of dendritic spine density, impaired long-term potentiation, and 
facilitated long-term depression in the hippocampus, in addition to the loss of the astrocyte glutamate 
transporters GLT-1 (EAAT2) and GLAST (EAAT1), and decreased glutamate uptake, resulting in a 
higher sensibility to glutamate excitotoxicity, that is one of the possible pathogenic mechanism in 
ALS (Figure 2) [62]. 
 
Figure 2. Possible effects of TGFB on different tissues of amyotrophic lateral sclerosis (ALS) patients. 
At the pre-symptomatic stage, the decreased activation of the TGFB pathway reduces its 
neuroprotective activity, and, at the same time, increases excitotoxicity induced by glutamate, with a 
lesser uptake by astrocytes. At the symptomatic stage, TGFB levels are largely increased, giving rise 
to microglia activation, and neuromuscular junction (NMJ) dismantling, thus leading to atrophy of 
skeletal muscle fibers. ALS disease progression could be promoted by a chronically altered TGFB 
pathway. A, astrocyte; M, microglia; MN, motor neuron; SkMf, skeletal muscle fibers. 
Motor nerve terminals show an intense TGFBRI and II immunoreactivity [63]; thus, they are 
expected to be responsive to TGFB. Furthermore, the Schwann cell side of the synapse and axons 
express TGFBRII, suggesting that motor neurons are exposed to TGFB along their full length. Indeed, 
motor neurons are surrounded by different cell types, all capable of producing and releasing TGFB: 
blood cells, Schwann cells, muscle fibers. During development, TGFB promotes motor neurons 
survival and saves them from naturally occurring cell death, due to competition for a limited amount 
of survival factors provided by all the cells that they interact with [64]. In primary motor neuron 
cultures, TGFB1 protects cells from damage caused by cytotoxic hypoxia or excitatory amino acids 
inducing an increase in cell viability, neuronal ATP levels, and protein content [65]. In vivo, its 
administration attenuates axotomy-induced motor neuron death, even if its rescue effect is not 
permanent [66]. TGFB2 is a motor neuron survival factor concentrated in the post-synaptic domain 
of mature rodent and human muscle fibers [67]. Nevertheless, in specific conditions, motor neurons 
are able to produce TGFB2 in an autocrine manner, probably to counteract peripheral (dendritic, or 
at the nerve terminal) apoptotic signals [63].  
Even if the comparative analysis of fALS and sALS tissues indicates the existence of common 
and distinct biological mechanisms driving the different forms of the pathology, altered levels of the 
TGFB1 pathway have been reported in motor neurons of most ALS models and patients. Recently, 
an analysis of DEGs and DEPs in induced pluripotent stem cells (iPSC)-derived motor neurons from 
Int. J. Mol. Sci. 2019, 20, x FOR PEER REVIEW 8 of 17 
 
patients with mutations in C9orf72 indicated TGFB and SMAD2/3 targets among the pathway most 
involved with a high correlation between significantly altered mRNA and proteins [68]. Similar 
results have been obtained in postmortem spinal motor neurons from sALS patients. The mutated 
TDP-43 protein aggregates form intracytosolic inclusion bodies that sequester pSMAD2/3 and 
SMURF2, an E3 ubiquitin ligase promoting the ubiquitin-dependent degradation of SMAD proteins, 
suggesting an impaired TGFB signal in motor neurons of sALS patients [69,70]. Interestingly, TDP-
43 inclusions of brain extra-motor neurons do not co-localize with pSMAD2/3, and its nuclear 
staining is preserved, indicating regional differences in the composition of the inclusions and in the 
impairment of TGFB signaling [70]. 
An excessive activation of the TGFB pathway has also been reported in ALS4 patients 
characterized by mutation in senataxin (SETX) gene. These patients present fewer R-loops (three-
stranded nucleic acid structures) and their differentially-expressed genes are highly enriched for 
activation of the TGFB pathway [71]. Principally, it is decreased in the expression of BAMBI, a TGFB 
pseudo receptor, which lacks the intracellular kinase domain and acts as a negative regulator, leading 
to an increased TGFB signaling. Indeed, in the same ALS4 patients, levels of pSMAD2/3 are increased 
in the anterior horn of the spinal cord [71]. 
TGFB/SMAD targets are abnormally regulated in iPSC-derived motor neurons from patients 
with mutSOD1, even if, in this case, they belong to downregulated gene sets [68]. Neuronal injuries, 
such as oxidative stress, rapidly up-regulate TGFB1 mRNA, inducing the expression of multiple 
genes involved in neuronal protection, and counteracting neuronal damage [72]. Reduced Tgfb1 
mRNA levels in the spinal cord of pre-symptomatic mutSOD1 mice could indicate a lack of the TGFB 
neuroprotective effect in the early stages of the disease [29]. With disease progression, Tgfb1 gene 
expression increases in the spinal cord, probably for the development of reactive astrogliosis [29,73]. 
In fact, it must be highlighted that all types of glial cells are able to produce and/or respond to TGFB. 
The role of glia-derived TGFB1 in the spinal cord of ALS patients and mice has been studied by Endo 
and colleagues [12]. They observed an upregulation of TGFB1 in the lumbar spinal cord of ALS mice, 
mainly in astrocytes. Furthermore, TGFB1 mRNA levels negatively correlated with the survival of 
ALS mice. Taking advantage of the ALS mice overexpressing TGFB1 in astrocytes and of the ALS 
mice with the astrocyte-specific deletion of TGFB1, they determined that astrocyte-derived TGFB1 
accelerates disease progression in ALS mice, preventing neuroprotective responses mediated by the 
microglia and T cells [12]. 
In the spinal cord of ALS mice, the TGFB signaling pathway is also altered. Tgfbr2 mRNA levels 
are increased [29] in agreement with other authors, indicating a higher TGFBR2 immunoreactivity 
[73], and higher levels of Tgfbr2 in human and mouse spinal cord ALS samples [74,75].  
In mutSOD1 mice, levels of pSMAD2 in the nuclei of lumbar motor neurons are significantly 
decreased already at the pre-symptomatic stage, while they are preserved at the cytosolic level as the 
expression of TGFBR1 and 2 [12,69,76]. This led to the hypothesis of an aberrant nucleo/cytosolic 
transport with an accumulation of cytosolic pSMAD2/3 immunoreactivity [69,76]. Moreover, the 
presence of pSMAD2 in glial nuclei is preserved. This hypothesis is also supported by the fact that 
physiological pSMAD2 levels in the nucleus are not recovered by overexpressing TGFB1 [12], and 
that the expression of Smad2 and Smad4 is decreased [29]. Otherwise, an up-regulation of SMAD4 in 
the spinal motor neurons of autopsied sALS cases has also been reported [77]. 
6. TGFB Pathway in ALS Skeletal Muscle 
In skeletal muscle, the expression of TGFB is related to normal processes such as growth, 
differentiation, regeneration, and stress response. However, continuously elevated levels of TGFB 
are linked to impaired regeneration and atrophy. TGFB blocks myogenic responses and stimulates 
fibrosis [78]. It inhibits the activation of MyoD and myogenin (two transcription factors regulating 
muscle cell differentiation) through the signaling of SMAD3 or by inactivating cyclin-dependent 
kinases [79,80]. Satellite cell activation is also prevented in the presence of TGFB, and muscle 
overexpression of TGFB leads to muscle weakness and atrophy [81,82]. Furthermore, TGFB has a 
dual role in the inflammatory process taking place after muscle injury: it acts first as a stimulating 
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factor, and then as a suppressor for muscle inflammatory response. Injured muscle fibers secrete 
TGFB, and in different disorders, its muscle levels are elevated [83]. Spinal and bulbar muscular 
atrophy (SBMA), a polyglutamine disease dependent on the expansion of the CAG repeat within the 
androgen receptor (AR) affects motor neurons and skeletal muscles and it is also associated with the 
disruption of TGFB signaling [84,85]. Mdx mice (a model of Duchenne muscular dystrophy) are 
characterized by myofiber degeneration and augmented TGFB1 signaling [86]. Furthermore, in this 
murine model, the neutralization of TGFB1 signaling may enhance the differentiation and fusion of 
the precursor satellite cells, suggesting a direct role for this cytokine in skeletal muscle regeneration 
[87].  
ALS muscle tissue is also characterized by alterations of the TGFB pathway. We reported 
increased levels of the Tgfb1 mRNA in the muscle of mice expressing mutSOD1 [28]. These changes 
are also gender-related, since male mice present an increased TGFB expression in muscle already at 
the pre-symptomatic stage, both at the mRNA and protein level, while in female animals, TGFB 
increases only at the symptomatic stage [29]. Tgfb mRNA levels are further increased with the 
administration of an anabolic/androgenic steroid (AAS), indicating that, at least at the muscular level, 
AAS might exert a detrimental role in ALS, since it might exacerbate some of the alterations induced 
by mutSOD1 [28,88]. Moreover, data obtained with the C2C12 muscle cell model indicate that an 
increase of the AR (that was obtained in vivo by stabilizing the receptor through a chronic AAS 
treatment) may also modify the effect of the wild type human SOD1, leading to an augmented TGFB1 
expression [28]. These data might help to explain gender differences in the risk to develop ALS [2]. 
Evidence in human confirmed the involvement of TGFB1 since we reported an increased TGFB1 
expression in muscle of female and male sporadic ALS patients with a significant gender effect [29], 
and other authors also reported the increase of TGFB1, 2, and 3 in ALS patient muscles [89,90]. It must 
also be highlighted that TGFB1 and TGFB3 mRNA show a negative correlation with muscle strength 
in ALS patients [90]. In the same manner, the increase of TGFB1 correlates with disease progression 
in mutSOD1 mice [28] and Smad1, 5, and 8 expression negatively correlates with mouse rotarod scores 
[91]. As a result, TGFB1 has been proposed as a possible biomarker of ALS progression [29,90,92]. 
The analysis of muscle lysates from ALS patients indicated a strong increase of TGFB1 protein 
[90]. Even if, in these samples, TGFB1 immunoreactivity has been detected in macrophages and 
lymphocytes surrounding the fibers and suggesting inflammatory infiltrated cells as the TGFB1 
source, we reported that the expression of mutSOD1 in C2C12 cells stimulates Tgfb1 expression [28], 
and C2C12 cells are able to respond to TGFB, increasing SMADs production and phosphorylation 
[90]. 
Regarding the intracellular pathways mediating TGFB functions in muscle cells, different works 
have evidenced changes in the levels of SMAD proteins. We reported an increased expression of 
SMAD2 and SMAD3 in symptomatic ALS mice, in agreement with Si and collaborators [29,90]. 
Evidence in ALS patients is more contradictory, reporting increased [89], diminished [29], or 
unchanged [90] SMADs muscle expression. These discrepancies might be due to the heterogeneity of 
ALS patients (sporadic vs. familiar), to the site of the biopsies (deltoid, tibialis anterior, vastus 
lateralis), duration of the pathology, site of onset, etc. R-SMADs enter into the nucleus through 
SMAD4, and in line with the work of Saris et al., we found a decreased Smad4 expression in muscle, 
suggesting a further site of dysregulation of TGFB intracellular signaling [93]. The involvement of 
other SMAD proteins (SMAD 1, 5, and 8, usually more involved in the BMP signaling pathway), has 
been reported [91]. BMP is one of the strongest hypertrophic signals in muscle; for this reason, the 
increase of these SMADs could represent a way to counteract denervation-induced atrophy. Whether 
SMAD changes are related to the progressive loss of motor neuron innervation or to a muscle 
pathological modification contributing to its atrophy and to disease progression has yet to be 
established. However, we reported that mutSOD1 toxicity can be exerted independently of its 
tendency to aggregate. At motor neuron level, mutSOD1 forms proteinaceous inclusions that alter 
SOD1 protein bioavailability and turnover [94] and reduce the protective effect exerted by wild type 
SOD1 against free radical reactive oxygen species [95]. On the contrary, in the gastrocnemius muscle 
of ALS mice, an increase of mutSOD1 levels was detected only at the terminal stage, and no high 
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molecular weight SDS-resistant species of mutSOD1 were identified, either in ALS mice or in C2C12 
cells expressing mutSOD1 [28,35]. 
The hypothesis of an impairment of TGFB signaling in motor neurons at the step of pSMAD 2/3 
translocation into the nucleus is also supported by data obtained in the muscle since, usually, TGFB1 
inhibits MyoD transcription through SMAD3, while in mutSOD1 mouse muscle, and in mutSOD1 
transfected C2C12 cells, we detected high levels of MyoD mRNA [28]. 
It has also been proposed that excessive oxidative processes may be a mechanism of activation 
of latent TGFB pool in ALS, as in other neurodegenerative diseases, leading to an increased TGFB1 
release from the complex [96]. 
TGFB1 is a potent inducer of fibrotic tissue formation, promoting the transformation of 
myoblasts into fibrotic tissue after an injury, inhibiting satellite cell activation, and impairing myocyte 
differentiation [86]. In the skeletal muscle of mutSOD1 expressing mice fibrosis is enhanced and 
correlates with TGFB levels, therefore, we can hypothesize that the beneficial effects of reducing 
TGFB levels could also be associated with a reduction of fibrosis [97]. 
7. TGFB and NMJ in ALS 
Since the first histological studies, recurrent denervation and reinnervation have been observed 
in the NMJs of ALS patients [98]. Because of that, it has been proposed to consider ALS also as a distal 
axonopathy, with pathological changes occurring at the NMJs prior to motor neuron degeneration 
and muscle fiber atrophy (see, for review [99]). 
TGFB pathway regulates the formation and stability of the NMJs. All the members of this 
tripartite synapse are able to produce and/or respond to TGFB. Muscle fibers express TGFB1, motor 
neuron terminals express TGFB receptors, and the synapse associated Schwann cells, also called 
terminal Schwann cells (TSCs, which are active components of the NMJ [100]), promote 
synaptogenesis at the NMJ via TGFB1 [101]. In this site, TGFB1 is capable of doubling the size of 
acetylcholine receptor clusters increasing the percentage of nerve–muscle contacts. It has also been 
demonstrated that this synaptogenic effect of TGFB1 might be ascribed to its ability to induce 
neuronal agrin expression [101]. Agrin is a proteoglycan important for the maintenance of the 
architecture of the postsynaptic membrane, known to be down-regulated in the muscle of ALS mice 
expressing mutSOD1 [22]. 
Recent studies indicate that alterations of the TSCs are present well before motor neuron 
terminal degeneration and the beginning of denervation in mutSOD1 expressing mice [102]. An 
anomaly appears as the absence of TSCs at many NMJs of the fast medial gastrocnemius, and with 
TSC cell body displacement at other NMJs of gastrocnemius or soleus muscle. This evidence could 
support the different extent of denervation between fast and slow muscles [102]. 
Among the factors secreted by muscle fibers and concentrated at the NMJ to promote synapse 
well-being, there is the fibroblast growth factor binding protein 1 (FGFBP1) [103]. FGFBP1 is a 
secreted factor that might potentiate the bioactivity of different members of the FGF family during 
reinnervation, by releasing sequestered FGF from the extracellular matrix [103]. The expression of 
this binding protein is known to be decreased in mutSOD1 mouse skeletal muscles before NMJ 
degeneration, and the deletion of FGFBP1 from mutSOD1 mice accelerates NMJ degeneration and 
disease progression [104]. The same authors reported also that TGFB1 is highly concentrated at NMJs 
of pre-symptomatic mutSOD1 mice, and represses FGFBP1 expression, indicating TGFB1 pathway 
as a potential target for preventing NMJ dismantling in ALS mice [104]. 
Moreover, other genetic models of ALS present NMJ modifications. For example, the loss of 
function of VAPB in Drosophila reduces the number of boutons that are also larger than in wild type 
flies, and with a highly disorganized microtubule network [105]. Again, a Drosophila ALS model 
expressing a mutant form of an ortholog of VAPB (resembling the loss of function phenotype), shows 
reduced pMAD (an ortholog of SMAD) at the NMJ and in CNS [106]. 
8. TGFB: A Target for ALS Treatment  
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The therapeutic potential of TGFB has been investigated, in order to develop new therapies for 
ALS.  
In a study performed with mutSOD1 expressing mice, SB-431542, a selective inhibitor of TGFBRI 
kinase activity, has been proven to extend animal survival, even if administered after disease onset; 
this led the authors to hypothesize that TGFB1 produced by astrocytes inhibits the neuroprotective 
response given by microglia and inflammatory cells and could be considered a negative prognostic 
factor [12].  
Moreover, the intraperitoneal injection of TGFB2 is able to acutely improve the motor 
performance of ALS mice. It reverses initial muscle weakness, permitting a better performance at 
rotarod test, probably through a marked trophic action on motor neurons, as can be inferred by motor 
neuron nuclei and axonal enlargement. Unfortunately, this advantage is transient, leading to an even 
more rapid progression of the disease [107].  
Antibodies neutralizing other members of the TGFB family have been tested in ALS models. For 
example, the prevention of myostatin binding to its receptor delayed the onset and the progression 
of the disease in ALS mice, even if without extending their survival [108,109]. 
9. Conclusions 
The pleiotropic effects of TGFB in ALS have been analyzed and are summarized in Figure 2. 
The imbalance of TGFB signaling has been linked to ALS progression. On one hand, at the level 
of the CNS, there is a lack of the neuroprotective effects of TGFB at the first stages of the disease; later, 
the strong increase of TGFB levels due to microglial stimulation shifts the CNS milieu toward a 
proinflammatory and neurotoxic environment. On the other hand, at the level of the skeletal muscle, 
the chronically increased TGFB signaling facilitates the development of atrophy and fibrosis in 
skeletal muscle fiber, and the process of NMJ dismantling. Furthermore, the higher pre-symptomatic 
levels of TGFB in male vs. female muscle support the evidence that males are more vulnerable than 
females in ALS. Whether muscle effects are the cause or the result of the progressive motor neuron 
degeneration remains to be established. 
Taken together, the data reviewed here support the hypothesis that the TGFB pathway may be 
considered critical for ALS etiology and progression. Thus, TGFB and its signaling pathway could 
represent a promising target for developing new therapies for ALS.  
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Università degli Studi di Milano e piano di sviluppo UNIMI—linea B (to V.C. and P.R.); Bando Straordinario 
per Progetti Interdipartimentali (Bando SEED 2019: #TDP-43-iPSC to V.C.) Italian Ministry of University and 
Research (MIUR), PRIN—Progetti di ricerca di interesse nazionale (n. 2015LFPNMN to A.P.; n. 2017F2A2C5 to 
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